Graphite Bio, Inc. (GRPH)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Graphite Bio, Inc. ("Graphite" or the "Company") (NASDAQ: GRPH). Investors who purchased Graphite securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Graphite and certain of its officers and/or directors have violated federal securities laws.
On or around June 25, 2021, Graphite conducted its initial public offering (“IPO”), issuing 14 million shares of common stock priced at $17.00 per share. Then, on March 21, 2022, Graphite issued a press release providing business updates and announcing is fourth quarter and fiscal year 2021 financial results. Among other items, Graphite disclosed that the early proof-of-concept data from the Phase 1/2 CEDAR clinical trial for GPH101 in sickle cell disease are now expected in 2023, attributing the delay “to impacts of the recent COVID-19 Omicron variant surge on patients and site resources and operations[.]” On this news, Graphite’s stock price fell $1.23 per share, or 15.15%, to close at $6.89 per share on March 21, 2022.
If you are aware of any facts relating to this investigation or purchased Graphite shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.